Study guide
27.3 Queries, Coding and Supported Clinical Meaning
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
27.3 Queries, Coding and Supported Clinical Meaning
Key Takeaways Explain This Topic AI
Queries request clarification, confirmation or supported correction.
Authorised site responses differ from sponsor/monitor review and query closure.
Medical coding should preserve supported clinical meaning rather than dictate a new diagnosis.
Last updated: October 2026
Queries, Coding and Supported Clinical Meaning
Note
Clinical Data Management (CDM) is the operational discipline that converts raw clinical trial observations into clean, validated, standardized, and statistically analyzable datasets for regulatory evaluation. The journey from initial point-of-care data capture to definitive Database Lock (DBL) requires continuous quality control through structured query workflows, international medical coding dictionaries, rigorous pharmacovigilance safety reconciliation, and multi-disciplinary blinded protocol deviation reviews. For the Clinical Research Associate, driving query resolution, preserving source integrity, and leading sites through pre-lock milestones represent critical core competencies.
A clinical trial may successfully enroll participants and execute every protocol-required procedure, but if the resulting data are plagued by uncodable medical terms, unresolved discrepancy queries, or discrepancies between the clinical database and the safety repository, the responsible team must assess and address the impact before planned analysis/reporting. Database Lock represents a controlled operational milestone restricting routine editing and defining a controlled dataset version for its intended use.
The Clinical Data Query Lifecycle
A Data Query (also termed a Data Clarification Form [DCF] or Discrepancy Note) is a formal communication generated within an Electronic Data Capture (EDC) platform requesting that the investigative site clarify, confirm, or correct clinical data entered on a Case Report Form.
The Three Origins of Data Queries
System/Automated Queries: Fired automatically by programmatic validation logic programmed into the EDC system. These operate according to the configured system workflow when values violate range boundaries, when mandatory fields are omitted, or when cross-form dates conflict.
Data Management (DM) Queries: Generated manually by sponsor or CRO Clinical Data Managers reviewing data listings for clinical plausibility, missing documentation across visits, or ambiguous medical descriptions.
CRA / Monitoring Queries: Generated manually by the CRA during on-site or remote Source Data Verification (SDV) and Source Data Review (SDR) when the monitor detects discrepancies between the primary source records and transcribed eCRF fields.
Regulatory Rules Governing Query Resolution
Strict DOA Authorization: Under ICH E6(R3), the Principal Investigator is responsible for the accuracy, completeness, and timeliness of all trial data reported to the sponsor. While the PI may delegate query resolution tasks to qualified clinical research coordinators via the Delegation of Authority (DOA) log, responses and corrections should be made by appropriately authorised personnel under the documented workflow .
Preserve the authorised workflow: A monitor must not answer for the site or make ad hoc data changes simply because staff are busy or a deadline is close. E6(R3) permits sponsor changes to investigator-entered data only when justified, agreed upon in advance by the investigator and documented. Use the actual controlled allocation of responsibilities; never impersonate site staff. Reviewing and closing a monitor query after a supported site response is distinct from supplying that response yourself.
Prohibition of "Fudge Factors": Site personnel must never fabricate explanations or alter source documents retroactively to satisfy a query. If an automated edit check flags an out-of-range pulse of 42 bpm in an athletic subject, the site must not artificially alter the source record to 60 bpm. Instead, the site confirms that 42 bpm was the true measured value and enters an explanatory note: "Confirmed correct: Subject is a marathon runner; baseline resting bradycardia clinically evaluated by PI."
Query Aging Metrics: Sponsors monitor Query Aging (the elapsed calendar days between query issuance and site resolution). The trial procedures define that sites resolve routine queries within specified deadlines, with urgent safety issues escalated promptly. The CRA tracks aging metrics and intervenes when site query backlogs exceed acceptable operational thresholds.
Medical coding and faithful clinical meaning
Coding groups varying clinical language for consistent review and analysis. Common dictionaries include MedDRA for events/medical conditions and WHODrug for medicines. Their detailed hierarchies are not additional references on ACRP's current CCRA list. A monitor's priority is clear, supported source and verbatim information, not changing a diagnosis to make a preferred code available.
Record an unambiguous term, relevant dates, medical assessment and the information requested by the protocol. If an abbreviation or compound phrase is unclear, seek qualified clarification. Do not assume every symptom must always be split or always absorbed into a diagnosis; apply the collection and coding conventions with medical review. Preserve what the investigator actually assessed and document any change.
For a medicine, exact product name, dose, unit, route, frequency, dates and indication can support interpretation. A trade name may refer to different formulations or combinations. Query missing information neutrally rather than substituting a familiar product. Coding is normally performed/reviewed by the assigned sponsor function; the CRA facilitates supported clarification through the investigator/site.
Serious Adverse Event (SAE) Reconciliation
In modern clinical trial execution, participant safety data are maintained in two parallel, independent databases:
The SAE Reconciliation Mandate
Because the clinical EDC database and the pharmacovigilance safety database ingest data through different pathways (routine eCRF entry vs. immediate SAE report forms), discrepancies can occur.
SAE Reconciliation is the formal, periodic, cross-functional auditing process conducted jointly by Clinical Data Management, Drug Safety, and Clinical Operations to identify and resolve discrepancies between the two repositories.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E9(R1) .